The current study provides primary evidence regarding the need for simultaneous regulation of hepcidin and EPO to enhance the efficacy of IV iron supplementation for the treatment of anemia under chronic inflammatory conditions. The gene discussed is HAMP; the disease is anemia (phenotype).